124 related articles for article (PubMed ID: 11194432)
21. Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer.
Paik ES; Kim TJ; Lee YY; Choi CH; Lee JW; Kim BG; Bae DS
J Gynecol Oncol; 2016 Sep; 27(5):e46. PubMed ID: 27329194
[TBL] [Abstract][Full Text] [Related]
22. [Program for early detection of ovarian cancer for women as prophylaxis provided at a municipal hospital].
Cnota W; Sodowski K; Olesiak-Andryszczak M; Pilch-Kowalczyk M
Wiad Lek; 2004; 57 Suppl 1():43-7. PubMed ID: 15884203
[TBL] [Abstract][Full Text] [Related]
23. [Computed tomography of uterine and ovarian cancer].
Masselot J; Galakhoff C; George M; Haie C; Michel G
Rev Fr Gynecol Obstet; 1987 Feb; 82(2):79-84. PubMed ID: 3563289
[TBL] [Abstract][Full Text] [Related]
24. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
[TBL] [Abstract][Full Text] [Related]
25. Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study.
Feinberg J; Carthew K; Webster E; Chang K; McNeil N; Chi DS; Long Roche K; Gardner G; Zivanovic O; Sonoda Y
Int J Gynecol Cancer; 2022 Feb; 32(2):159-164. PubMed ID: 34969828
[TBL] [Abstract][Full Text] [Related]
26. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
[TBL] [Abstract][Full Text] [Related]
27. [Transvaginal color doppler ultrasonography and CA125 detection in surveillance of ovarian malignant tumors after operation].
Zeng H; Pei XQ; Zheng DM; Zhao YL; Chen XY
Ai Zheng; 2006 Oct; 25(10):1296-9. PubMed ID: 17059780
[TBL] [Abstract][Full Text] [Related]
28. The role of CT in the evaluation of ovarian malignancy.
Amendola MA
Crit Rev Diagn Imaging; 1985; 24(4):329-68. PubMed ID: 3896652
[TBL] [Abstract][Full Text] [Related]
29. [Diagnostic potential of ultrasound examination for tumor recurrence and metastasis].
Meshkova IE; Kostromina EV; Trouk EB
Vopr Onkol; 2000; 46(1):84-7. PubMed ID: 10789232
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis and Management of Adnexal Masses.
Biggs WS; Marks ST
Am Fam Physician; 2016 Apr; 93(8):676-81. PubMed ID: 27175840
[TBL] [Abstract][Full Text] [Related]
31. [Transvaginal echography in clinical practice].
Davydov AI
Akush Ginekol (Mosk); 1991 Aug; (8):71-6. PubMed ID: 1755501
[No Abstract] [Full Text] [Related]
32. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation.
Wilder JL; Pavlik E; Straughn JM; Kirby T; Higgins RV; DePriest PD; Ueland FR; Kryscio RJ; Whitley RJ; Nagell Jv
Gynecol Oncol; 2003 May; 89(2):233-5. PubMed ID: 12713985
[TBL] [Abstract][Full Text] [Related]
33. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
Petignat P; Vajda D; Obrist R
Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
[TBL] [Abstract][Full Text] [Related]
34. [Problems in connection to treatment of ovarian tumors and fertility preservation].
Shen K
Zhonghua Fu Chan Ke Za Zhi; 2003 Aug; 38(8):489-92. PubMed ID: 14627038
[No Abstract] [Full Text] [Related]
35. The association of RCAS1 serum concentration with the reversibility or irreversibility of the process of immune cytotoxic activity restriction during normal menstrual cycle, cancer relapse, and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas.
Dutsch-Wicherek M; Wicherek L
Am J Reprod Immunol; 2008 Mar; 59(3):266-75. PubMed ID: 18275520
[TBL] [Abstract][Full Text] [Related]
36. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients.
Fehm T; Heller F; Krämer S; Jäger W; Gebauer G
Anticancer Res; 2005; 25(3A):1551-4. PubMed ID: 16033059
[TBL] [Abstract][Full Text] [Related]
38. Pelvic examination, transvaginal ultrasound and transvaginal color Doppler sonography as predictors of ovarian cancer.
Buckshee K; Temsu I; Bhatla N; Deka D
Int J Gynaecol Obstet; 1998 Apr; 61(1):51-7. PubMed ID: 9622173
[TBL] [Abstract][Full Text] [Related]
39. [Metabolic imaging with positron-emission tomography in the advanced-stage ovarian cancers].
Grahek D; Hassan-Sebbag N
Bull Cancer; 2009 Dec; 96(12):1163-71. PubMed ID: 19948451
[TBL] [Abstract][Full Text] [Related]
40. Palliative surgery for intestinal complications of advanced, recurrent gynaecologic malignancy.
Mäkelä J; Kairaluoma MI; Kauppila A
Acta Chir Scand; 1987 Jan; 153(1):57-61. PubMed ID: 2437746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
